Pfizer Parecoxib, Oporia Setbacks Reflect Tougher FDA Stance, CEO Says

Pfizer's research & development productivity has been impacted by a more difficult, risk-averse regulatory environment at FDA, CEO Hank McKinnell said during an earnings call Oct. 20

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet